Assessment of drug–drug interaction potential with EDP‐305, a farnesoid X receptor agonist, in healthy subjects

por Ahmad, Alaa, Adda, Nathalie
Publicado 2022

EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects

por Marotta, Christine, Ahmad, Alaa, Luo, Ed, Oosterhaven, Jart, van Marle, Sjoerd, Adda, Nathalie
Publicado 2022

LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study

por Coakley, Eoin, Ahmad, Alaa, Larson, Kajal, McClure, Ty, Lin, Kai, Lin, Kai, Tenhoor, Kursten, Eze, Kingsley, Noulin, Nicolas, Horvathova, Veronika, Murray, Bryan, Baillet, Mark, Mori, Julie, Adda, Nathalie
Publicado 2019

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

por Zoulim, Fabien, Fournier, Claire, Habersetzer, François, Sprinzl, Martin, Pol, Stanislas, Coffin, Carla S, Leroy, Vincent, Ma, Mang, Wedemeyer, Heiner, Lohse, Ansgar W, Thimme, Robert, Lugardon, Karine, Martin, Perrine, Bastien, Bérangère, Sansas, Benoit, Adda, Nathalie, Halluard, Celine, Bendjama, Kaïdre, Brandely, Maud, Inchauspé, Geneviève
Publicado 2019

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

por Kieffer, Tara L., De Meyer, Sandra, Bartels, Doug J., Sullivan, James C., Zhang, Eileen Z., Tigges, Ann, Dierynck, Inge, Spanks, Joan, Dorrian, Jennifer, Jiang, Min, Adiwijaya, Bambang, Ghys, Anne, Beumont, Maria, Kauffman, Robert S., Adda, Nathalie, Jacobson, Ira M., Sherman, Kenneth E., Zeuzem, Stefan, Kwong, Ann D., Picchio, Gaston
Publicado 2012